Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. The company was founded by pioneers of CRISPR-Cas biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/17/16 | $30,000,000 | Series B |
5 Prime Ventures Anterra Capital F-Prime Capital Partners Heritage Group Maverick Capital Mission Bay Capital Novartis Venture Funds Pontifax | undisclosed |
| 03/03/21 | $115,000,000 | Series C |
AbbVie Biotech Ventures Adage Capital Management Avego Bioscience Capital Avidity Partners Farallon Capital Management  Invus Janus Henderson Investors Leukemia & Lymphoma Society Therapy Acceleration Program LifeSci Venture Partners Monashee Investment Management PFM Health Sciences Ridgeback Capital Management | undisclosed |
